News
GSK pursues $10.6bn takeover of cancer biotech Nuvalent
GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Patients
ASCO 26: Three cancer survivors share lessons for the field
In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.
Oncology
ASCO 2026: Chinese firms take a front seat in oncology, with...
Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Oncology
Cancer patients don’t care where the breakthrough happened. ...
National Cancer Survivors’ Day highlighted decades of progress against cancer, but oncology faces a new challenge.
News
J&J lights up $1bn offer for pan-KRAS developer Firefly
Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
